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RESPIRATORY-RELATED DISORDERS - Cost Studies
PRS4
PubLIC HEALTH AnD ECOnOmIC ImPACT Of 13-VALEnT PnEumOCOCCAL 
COnjugATE VACCInE (PCV13) In PubLIC AnD PRIVATE SYSTEm VERSuS PPSV23 
AnD nO VACCInATIOn In OLDER ADuLTS
Ferreira CN1, Santana CF2, Rufino C1
1Pfizer Brasil, São Paulo, Brazil, 2Pfizer, São Paulo, Brazil
Objectives: Pneumococcal disease is a public health concern worldwide. This study 
evaluates the public health and economic impact of 13-valent pneumococcal con-
jugate vaccine (PCV13) vaccination in Brazilian adults aged ≥ 50 years. MethOds: 
A cohort model with a Markov-type process depicting expected risk, consequences 
and costs of pneumococcal disease was developed. PCV13 effectiveness was based 
on data from CAPiTA; the 23-valent polysaccharide vaccine (PPSV23) effectiveness 
was based on published literature. Pneumococcal disease rates were based on data 
from DATASUS. Outcomes, direct and indirect costs (in BRL) were evaluated from a 
Brazilian public (n= 20,228,045) and private (n= 11,396,682) payer perspective over 
a 5 year time horizon. Results: From a public payer perspective, vaccination with 
PCV13 versus PPSV23 avoided 676,031 PD cases, 853 deaths with BRL 2,32 million 
cost saving. An expected 696.970 PD cases and 29.644 deaths would be avoided for 
PCV13 versus no vaccine 2,16 million cost savings. From a private payer perspec-
tive, vaccination with PCV13 versus PPSV23 avoided 410,302 PD cases and 1,074 
deaths with a 1.27million cost-savings. An expected 420,159 PD cases and 18,482 
deaths would be avoided for PCV13 versus no vaccine with a 1.69 million cost-
savings. cOnclusiOns: PCV13 prevents more pneumococcal disease cases and 
deaths than PPSV23 or no vaccine and is expected to save economic resources (direct 
and indirect) from a private perspective, and cost-effective from a public perspective.
PRS5
COSTO DE TubERCuLOSIS En LOS ESTAbLECImIEnTOS DE SALuD DEL PERú
Timana-Ruiz R1, Sobrevilla-Ricci A2, Mosqueira-Lovón R2, Gutierrez-Aguado A3,  
Escobedo-Palza S4
1SOMPEGS, Lima, Peru, 2Abt Associates-HFG Peru, Lima, Peru, 3UNMSM, Lima, Peru, 4SPEAS, 
Lima, Peru
ObjectivOs: Estimar los costos de la Tuberculosis (TBC) en los establecimien-
tos del Ministerio de Salud del Perú. MetOdOlOgíAs: Se realizó una evaluación 
económica parcial de tipo costo de enfermedad (CE). La población de estudio fue 
una cohorte hipotética de pacientes afiliada al Seguro Público de Salud (Seguro 
Integral de Salud) en el Perú. Los costos se estimaron desde la perspectiva del 
financiador tomados para el año 2014. La definición de los esquemas de manejo 
clínico (procedimientos médicos y medicamentos para el diagnóstico, tratami-
ento y seguimiento de la enfermedad) provienen de las Condiciones Asegurables 
del Plan Esencial de Aseguramiento en Salud (PEAS). Cada esquema de manejo 
clínico se ha estimado con la metodología de costeo estándar. El costo total 
fue ajustado por factores de oferta, demanda y adherencia. ResultAdOs: La 
cohorte hipotética de TBC es de 13,808 personas para el año 2014 (Incidencia 
de TBC Pulmonar: 0.11%, incidencia de TBC Extrapulmonar: 0.02%, incidencia 
de TBC con complicaciones: 0.01%, incidencia de TBC Multidrogoresistente: 
0.0036%). El costo total para TBC es de 27,443,865 dólares correspondiendo 
para TBC Pulmonar 23,666,252 dólares, TBC Extrapulmonar 1,501,742 dólares, 
TBC con complicaciones 935,552 dólares y para TBC Multidrogoresistente es 
de 1,340,319 dólares. El costo total correspondiente a diagnóstico es 1,302,884 
dólares (4.7%), tratamiento 24, 205,776 dólares (88.2%) y para seguimiento 1,935,206 
dólares (7.1%). El costo fijo correspondió a 12,538,706 dólares (45.7%) y el costo 
variable a 14,905,159 dólares (54.3%). cOnclusiOnes: El costo anual total para 
Tuberculosis en el Perú se estimó en 27,443,865 dólares. Este monto representa 
el 14.1% del presupuesto ejecutado el año 2014 en el Programa Presupuestal 016 
TBC –VIH/SIDA.
PRS6
COST Of ILLnESS (OuT Of POCkET COSTS PAID bY PATIEnT) fOR T.b In 
QuETTA CITY, PAkISTAn
ul Haq N1, Sattar A1, Iqbal Q1, Naseem A1, Bashir S2, Baloch M1
1University of Balochistan, Quetta, Pakistan, 2University of Sargodha, Sargodha, Pakistan
Objectives: The objective of study is to measure the cost of illness (out of 
pocket costs paid by patients) for T.B in Quetta city, Pakistan. MethOds: Cross 
sectional study was performed on TB patient in Fatima Jinnah chest hospi-
tal Quetta. The TB patients who were registered in hospital were interviewed 
to determine the out of pocket cost paid by TB patients by using standardized 
data collection tool. The descriptive statistics was used to present the data. All 
analyses were performed using SPSS 20.0. Results: The total of 70 TB patients 
were agree to participate in the study. Majority (62%, n= 44) were females with 
rural residency 51.4%, n= 36). Majority of patients had monthly income were 
8000-15000. The total average out of pocket cost was Pk. Rs. 11,685 per month 
for an individual patient. In addition, it was calculated that a patient spend Pk. 
Rs. 292 for diagnostic tests including chest x-ray, additional medicine purchased 
were of Pk. Rs. 1465, travel cost were Pk. Rs. 3,485 , special food cost were Pk. 
Rs. 2,128 rupees accommodation cost were Pk. Rs. 3,825 rupees, & the other 
cost were Pk. Rs. 490. It is worth mentioning here that all the medication and 
other treatment cost is paid by the government. cOnclusiOns: The study con-
cluded that although government paid all the medication and other treatment 
cost for TB patients, yet patient had to bear a high amount of money from his 
pocket which put additional burden to the poor patient suffering with a disease 
like TB.
12.5 million). cOnclusiOns: Colombian decision makers in health could largely 
benefit by controlling relapses for these types of patients. This study is one of the 
first approaches at quantifying the impact of the disease and its relapse. Policy 
measures should consider this data for addressing mental health in a systematic 
and conjoint approach.
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
PRS1
EVALuATIOn AnALYSIS Of SmOkIng POPuLATIOn In uLAAnbAATAR
Baasanjab Z1, Sonomjamts M1, Gombo E2
1Mongolia National University City of Medical Sciences,SCHOOL OF PHARMACY AND BIO-
MEDICINE, Ulaanbaatar, Mongolia, 2Mongolian National University of Medical Sciences, 
ulaanbaatar, Mongolia
Objectives: 1. To study health effect of smoking by questionnaires and tests. 
2. To study by comparing smoking population’s function of the lung with non-
smoker’s function of the lung. MethOds: 1201 people has participated for the 
research study and they were 20-39 years of age, and older than 40 years old, also 
study has taken in Ulaanbaatar at the same time. Research study included 79 
questions from “Adult core questionnaire” study of chronic respiratory diseases 
in the Asia-Pacific and spirometer analysis has done too. Results: The smok-
ing population by age and gender in Ulaanbaatar. AGE Male Smoking/%/ Female 
Smoking/%/ 20-29 194 75.5 161 19.4 30-39 121 79.3 134 28.4 40-49 153 78.4 152 
24.4 cOnclusiOns: Research study shows that 49.4% of total population and 
76.9% of males, 21.4% of females have been smoking for their lives with some 
circumstances in Ulaanbaatar. Also study shows that 30-39 years old, 70 years 
old females are smoking more than other ages particularly. For males smoking is 
in equal level for all ages. Function of lungs has changed depending on smoking 
and total years of smoking.
PRS2
fLuTICASOnE PROPIOnATE VERSuS buDESOnIDE OR bECLOmETHASOnE AS 
mOnOTHERAPY TREATmEnT fOR ASTHmA PATIEnTS - A SYSTEmATIC REVIEw
Saturnino LT, Salgado JB, Penha MF
GlaxoSmithkline, rio de janeiro, Brazil
Objectives: compare the efficacy and the safety of fluticasone propionate in the 
management of moderate to severe asthma in adults and children to the inhaled 
corticosteroids currently available in the public health care system in order to 
present an alternative therapy to the Brazilian government. MethOds: a sys-
tematic review of the MEDLINE, the Cochrane Library and Centre for Reviews and 
Dissemination (CRD) databases was conducted until September 2014, including 
randomized clinical study and systematic reviews about comparison between flu-
ticasone propionate and budesonide or beclomethasone, not associated with other 
medications. There was no age limit and the assessed endpoint was pulmonary 
function through morning and evening Peak Expiratory Flow Rate, Forced Expiratory 
Volume in one second, exacerbation and adverse events. The quality of the stud-
ies was measured by Grades of Recommendation, Assessment, Development and 
Evaluation. Results: there were 788 articles identified in MEDLINE, 231 in The 
Cochrane library and 46 in CRD, among all of these, 259 were duplicates, remaining 
806 to title analysis. In the final analysis, 21 articles were included – 3 system-
atic reviews and 18 randomized clinical studies. All systematic reviews showed a 
strong recommendation in favor of the new technology and high methodological 
quality. Among the clinical studies, 9 of them compared fluticasone propionate 
to beclomethasone and the others 9 to budesonide. The study results showed no 
statistically significant difference between the compared medicines. According to 
the results, fluticasone propionate is effective and well tolerated for the treatment 
of moderate to severe asthma, in adults and children, as well as beclomethasone 
and budesonide. cOnclusiOns: from this perspective, the inclusion of fluticasone 
propionate in the Brazilian Clinical Protocol and Therapeutic Guidelines could rep-
resent an extension of the therapeutic arsenal, especially, for the pediatric popula-
tion that have few options of treatment. Funding for this study was provided by 
GlaxoSmithKline, study HO-14-15763.
PRS3
OuT HOSPITAL DRug COnSumPTIOn In THERAPY Of ObSTRuCTIVE 
PuLmOnARY DISEASE In SERbIA In THE PERIOD fROm 2007 TO 2012
Milijasevic B, Tomic Z, Milijasevic D, Tomic N, Raskovic A
Medical Faculty of Novi Sad, University of Novi Sad, Novi Sad, Serbia and Montenegro
Objectives: Non infectious chronic diseases become one of the most frequent 
cause of morbidity all around the world and they are results of interactions 
between man and his environment. This group of diseases includes also chronic 
obstructive pulmonary disease (COPD), which explains why medications for the 
treatment of this disease take a large part in the consumption. The aim of this 
study was to analyze the consumption of medications in COPD in Serbia and 
in Norway in period from 2007 to 2012. MethOds: The data about the use of 
medications in Serbia were taken from the Agency for Drugs and Medical Devices 
of the Republic of Serbia. The data about the use of medications in Norwey were 
taken from official website of the Norwegian healthcare system. Results: Total 
consumption of medications for the treatment of respiratory diseases in Serbia 
from 2007 to 2012 was lower than the comnsumption of the same medications in 
Norway in the same time of period. The utilized medications of R group in both 
countries was very uneven in this period of time. Between the subgroups, the most 
frequently used medications were those for the chronic obstructive pulmonary 
disease (R03). cOnclusiOns: The consumption of medications in Serbia from 
2007 to 2012 was higher than in Norway. While analysing the consumption of 
medications we can make conclusion that the structure of the utilized medica-
tions in Serbia is not appropriate and is not similar to the farmacoterapeutic 
practice in well developed Norway. This research was supported by Provincial 
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una estrategia dominante debido a que mostró una mayor mejoría en un IT que 
refleja efectividad y seguridad, a un menor costo de tratamiento.
PRS10
COSTO - EfECTIVIDAD DE LA COmbInACIOn DE gLICOPIRROnIO/InDACATEROL 
VS. SALmETEROL/ fLuTICASOnA (COmbInACIOn DE DOSIS fIjA – CDf) En EL 
mAnEjO DE LOS PACIEnTES COn EnfERmEDAD PuLmOnAR ObSTRuCTIVA 
CROnICA (EPOC) En COLOmbIA (SuR AméRICA)
Karpf E1, Londoño D2, Olaya A1
1Novartis Colombia, Bogotá, D.C., Colombia, 2Director de Salud Pública de la Fundación Santa Fe 
de Bogotá. Bogotá, Colombia, Bogotá, D.C, Colombia
ObjectivOs: Estimar la costo efectividad de glicopirronio/indacaterol, frente 
a Salmeterol + fluticasona, para el tratamiento de la Enfermedad Pulmonar 
Obstructiva Crónica (EPOC) desde la perspectiva del sistema de salud colombi-
ano. MetOdOlOgíAs: Un modelo de microsimulación fue diseñado para estimar 
los beneficios clínicos y económicos asociados con la combinación glicopirronio/
indacaterol versus Salmeterol + fluticasona desde la perspectiva del sistema de 
salud colombiano. Los resultados de efectividad fueron medidos en años de vida 
ajustados por calidad y la eficacia fue basada sobre la mejoría inicial en el Volumen 
Espiratorio Forzado en el primer segundo (VEF1), tomado de los resultados de los 
estudios ILLUMINATE(5) and TORCH(12). Los ciclos de duración fueron trimes-
trales en un horizonte de tiempo a 5 años. La tasa de descuento utilizada para 
costos y beneficios fue del 5% anual. Los costos de la enfermedad se calcularon a 
partir de la revisión de historias de los pacientes atendidos en una institución de 
salud de Bogotá y los costos de los medicamentos se tomaron de la base de datos 
SISMED [11,12]. ResultAdOs: Bajo un horizonte de tiempo a 5 años con cortes a 
uno y tres años los años de vida ajustados por calidad de indacaterol/glicopirronio 
frente a salmeterol/fluticasona fueron de 0,001, 0,013 y 0,038 respectivamente con 
un costo incremental de -$116.747, $13.328 y $ 302.834 y una relación de costo/
efectividad incremental (ICUR) de $-199.881.605, $1.039.394 y $ 8.028.849, siendo 
indacaterol/glicopirronio una alternativa costo ahorradora en el primer año y 
costo - útil en el tercer y quinto año desde la perspectiva del sistema de salud 
colombiano. cOnclusiOnes: Los resultados muestran que la única combinación 
LABA/LAMA disponible en el mercado colombiano (indacaterol/glicopirronio) es 
costo – útil para el manejo de los pacientes con la EPOC que representan una carga 
económica importante para el sistema de salud colombiano.
PRS11
A PROSPECTIVE PRESCRIPTIOn COST AnALYSIS Of ASTHmA mEDICATIOn
Khan AH1, Aftab RA1, Sulaiman SA1, Ali I2
1Universiti Sains Malaysia, Pulau Pinang, Malaysia, 2General Hospital Penang, Pulau Pinang, 
Malaysia
Objectives: To review patient’s prescriptions and calculate direct cost for the 
treatment and management of asthma MethOds: A prospective cross-sectional 
detailed review of 180 prescriptions written by 6 doctors was conducted at respira-
tory department of hospital pulau pinang, Malaysia. Medication price was confirmed 
from the hospital formulary. Interview with the key personals were conducted to 
identify activities of each service provided to asthma patients. This was followed 
by determination of time taken to complete each activity using stopwatch. The 
duration was captured 15 times for each for three alternate days and summarized 
as the mean time (minutes) for each activity. The cost of each employee per single 
activity was obtained by multiplying the mean time (minute) spent by that employee 
doing a specific activity by his/her salary per minute Results: A total of 6 different 
classes of medications were prescribed to 180 asthma patients. β agonist was the 
most prescribed class of asthma medication that included Salbutamol 72 (39.8) and 
albuterol 20 (11) followed by Corticosteroids that included budisonide 59 (32.8%), 
prednisolone 16 (8.8%) and fluticasone 11 (6.1%). Fifty one (28.3%) units of budiso-
nide/formoterol combination medication were prescribed followed by fluticasone/
salmeterol 40 (22.2%). A total of RM 10610.79(USD) medication were prescribed to 
180 asthma patients with average cost of RM 59.08 per patient. The combination 
medication of budisonide/formoterol RM.5253 (USD) made the majority of total 
cost of asthma medication. Spirometry was performed for all 180 patients at every 
hospital visit that costed RM 5400.00. The cost of services provided by doctors and 
nursing staff for 180 asthma patients for single visit was RM 1198.8 and RM 331.2 
respectively cOnclusiOns: Combination medication adds a substantial cost to 
over all asthma cost. Careful selection of asthma pharmacotherapy can greatly 
reduce medication cost without compromising on treatment outcomes
PRS12
COST-EffECTIVE EVALuATIOn Of PIRfEnIDOnE fOR TREATIng IDIOPATHIC 
PuLmOnARY fIbROSIS In mExICO
Pozo L1, Paladio-Hernández JÁ2
1GRUFESA, Mexico City, Mexico, 2Independent Consultant, Cuautitlán Izcalli, Mexico
Objectives: Idiopathic pulmonary fibrosis is a chronic, progressive, and fatal 
lung disease that is characterized by irreversible loss of lung function. Pirfenidone 
is an oral antifibrotic therapy for the treatment of idiopathic pulmonary fibrosis 
with significant effects on reducing disease progression and exacerbations. The 
objective of this analysis is developing a cost-effectiveness analysis comparing 
pirfenidone vsthe current pharmacological alternatives available. MethOds: 
Pirfenidone is compared to Prednisone, azathioprine, and N-acetylcysteine in a 
cost-effectiveness analysis. A Markov model was developed to estimate incremen-
tal costs and benefits in this population of patients using a 1 year time horizon. 
The model comprised the following mutually exclusive health states: free progres-
sion, progression (defined as the time to the first occurrence of exacerbation) and 
death. Transition probabilities were obtained from clinical trials and the scientific 
literature. Disease costs and exacerbation costs derived from the IMSS’ Groups 
Related to Diagnosis (GRD). Costs were converted to UD dollars (1 USD = 15.42 
MXN). The perspective of the analysis was that of the Mexican Social Security 
Institute (IMSS). Results: Pirfenidone offers statistically significant improve-
PRS7
buRDEn Of COST In bROnCHIOLITIS ObLITERAnS SYnDROmE (bOS): 
PREDICTIOnS fOR THE nExT DECADE
Jones’ CA1, Chapman DG1, Fernandez L1, Mesa OA2, Peters C3
1University of Vermont College of Medicine, Burlington, VT, USA, 2Therakos, Inc., Wokingham, 
Berkshire, UK, 3Therakos, Inc., West Chester, PA, USA
Objectives: Transplanted lungs present much higher rates of complication and 
acute rejection than in other solid organ transplants, both immediately follow-
ing surgery and throughout the patient’s life. The most common life-threatening 
risk following lung transplantation is a disease called bronchiolitis obliterans 
syndrome (BOS), a late complication when compared to early transplant-related 
mortality. This disease has been found to occur in approximately 50% of all lung 
transplants, but can also result (with 5.5% incidence) from stem cell transplanta-
tion. The majority of such transplant survivors will have been in gainful employ-
ment prior to surgery and yet half will live with or be at risk for developing BOS. 
There are more than 10,000 people living with a transplanted lung. The delayed-
onset nature of BOS means that its prevalence overshadows its incidence. Our 
objective was to estimate this burden of cost from the human capital perspective, 
projected for the decade ahead. MethOds: Transplant statistics were evaluated 
using data from both the United Network for Organ Sharing (UNOS) and Leukemia 
and Lymphoma Society (LLS). Prevalence of BOS, time delay to onset, treatment 
costs, family and caregiver costs, average wage assumptions, and age-specific 
opportunity costs were evaluated from published sources, adjusted for inflation 
and projected over a ten-year time horizon. Results: BOS presents a burden on 
the success measures of many settings. Over the next decade, 14,771 future BOS 
patients are estimated to accrue 301,658 years of lost wages. This cumulative lost 
workforce could cost society $13,540,876,856 ($13.5B). Assuming employability 
prior to BOS, this cost is markedly ($13.5B vs. $1.6B) more than the estimated ten-
year cost of treatments, including diagnostics, drugs and devices. cOnclusiOns: 
BOS will continue to present a substantial economic burden to society the world 
over that is far beyond its healthcare cost, due to the foreshortened exit of thou-
sands from the paid workforce.
PRS8
TRATAmIEnTO AmbuLATORIO VERSuS HOSPITALARIO RELACIOnADO A 
AguDIzACIOnES En PACIEnTES COn ASmA DESDE unA PERSPECTIVA 
InSTITuCIOnAL PubLICA mExICAnA
Huicochea-Bartelt JL1, Camacho-Cordero LM2, Herran S1
1Boehringer Ingelheim, Distrito Federal, Mexico, 2Health Consoultings, Distrito Federal, Mexico
ObjectivOs: Estimar y comparar el uso y frecuencia de recursos médicos directos 
de atención de las agudizaciones por Asma a nivel ambulatorio y hospitalario, desde 
la perspectiva del Instituto Mexicano del Seguro Social (IMSS). MetOdOlOgíAs: 
De enero a diciembre del 2013, se realizó un estudio retrospectivo para estimar el 
costo médico directo de las agudizaciones de Asma. Tanto el patrón de tratamiento, 
como la categorización de las agudizaciones fueron aquellos establecidos por la 
institución (guía de tratamiento IMSS). Los registros de pacientes fueron obtenidos 
de bases electrónicas públicas para una cohorte de pacientes con agudizaciones de 
Asma. El tratamiento ambulatorio y hospitalario fueron los criterios para establecer 
el uso y frecuencia de recursos médicos, incluyendo consultas médicas familiares 
y de especialidades, consultas de urgencia, hospitalizaciones, estudios de labora-
torio y gabinete y uso de medicamentos. Los costos unitarios fueron obtenidos de 
tabuladores y compras públicas (2014 IMSS). Mediante un análisis estadístico se 
obtuvo la media en costos. ResultAdOs: En 2013, se reportaron 7,591 episodios 
de agudización de Asma, de los cuales 5,274 corresponden a pacientes hospitali-
zados. Se observó un promedio de 4.5 días de estancia hospitalaria en el horizonte 
estudiado. El costo anual promedio de tratamiento de las agudizaciones en cuidado 
hospitalario y ambulatorio fue de $96,223 y $20,274 respectivamente. Un análisis 
detallado de costos del cuidado hospitalario versus el cuidado ambulatorio dem-
ostró un aumento significativo en el uso de medicamentos (70%) y consultas de 
especialidades (50%) entre otros. cOnclusiOnes: En el tratamiento de episodios 
de agudización en Asma, el costo agregado por año del cuidado hospitalario versus 
el ambulatorio se estimo es 79% mayor. Reducir el riesgo de los sufrir estos episo-
dios con la elección correcta de tratamiento sería relevante para las instituciones 
Mexicanas.
PRS9
EVALuACIOn ECOnOmICA DE LOS PRInCIPALES ESTEROIDES InTRAnASALES 
uTILIzADOS PARA EL TRATAmIEnTO DE PACIEnTES PEDIATRICOS COn RInITIS 
ALERgICA En COLOmbIA
Rodriguez-Martinez CE1, Sossa-Briceño MP1, Vladimir Lemos E2
1Universidad Nacional de Colombia, Bogota, Colombia, 2MSD Colombia, Bogota, Colombia
ObjectivOs: El objetivo de este estudio fue comparar la costo-efectividad 
del furoato de mometasona (FM) en comparación con el dipropionato de 
beclometasona (DB) en pacientes pediátricos con rinitis alérgica (RA) en 
Colombia. MetOdOlOgíAs: Se desarrolló un árbol de decisiones para estimar 
la costo efectividad del FM en comparación con el DB para el tratamiento de 
pacientes pediátricos con RA en un período de tiempo de 12 meses. Los datos de 
efectividad se obtuvieron de un estudio publicado en el que los autores realizaron 
una revisión sistemática de la literatura. Los datos de costos se obtuvieron de las 
cuentas médicas de un hospital pediátrico, y del manual nacional de precios de 
medicamentos. La perspectiva del estudio fue el del Sistema de Salud colom-
biano. Los desenlaces fueron tres medidas de efectividad y seguridad, resumi-
dos en un índice terapéutico (IT) ResultAdOs: Para el análisis de caso base, el 
modelo mostró que comparado con el DB, el tratamiento con FM se asoció con 
menores costos de tratamiento (US$229.78 vs. 289.74 costo promedio por paciente 
en 12 meses) y una mayor mejoría en el IT (0.9724 vs. 0.8712 puntos en prome-
dio por paciente en 12 meses), considerándose por tanto una estrategia domi-
nante. cOnclusiOnes: El presente estudio muestra que en Colombia, comparado 
con el DB, el tratamiento con FM para pacientes pediátricos con rinitis alérgica es 
